anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a novel submicron system for the oral administration of proteins. An effective oral carrier for proteins should shield its content against the gastrointestinal tract proteases and be capable of facilitating the uptake of the protein drug across the gastrointestinal epithelium. The present invention relates to production of gelled particles which comprises a protein drug susceptible to enzymatic degradation by enzymes and acid conditions in the stomach, a polymeric matrix which undergoes precipitation-swelling process, and two-layer-coating materials which are themselves capable of enhancing absorption of said drug across the intestinal mucosal tissues and of inbihiting degradation of said drug by gastric enzymes. Insulin-loaded particles with appropriate submicron size for gastrointestinal absorption were made of natural occurring polymers by emulsification-based method and proved to be gastric pH and protease protective. Effects on glycemia were observed during 14 h after their oral single administration to rats, achieving 42% of pharmacological activity compared to subcutaneous administration. Postprandial rise in blood glucose was suppressed and insulinemia levels increased by a factor of seven. The relative oral bioavailability of insulin calculated over 8 h by comparison with a subcutaneous injection of free insulin was 34%.
This is a 2-part, open-label (all people know the identity of the intervention) multicenter (when more than 1 hospital or medical school team work on a medical research study), Phase 2 study to evaluate the safety and efficacy of the combination of siltuximab plus mitoxantrone versus mitoxantrone in participants with metastatic HRPC who have received 1 prior Docetaxel-based chemotherapy (treatment of disease, usually cancer, by chemical agents) regimen (pattern of giving treatment). Part 1 of the study is single arm where participants will receive mitoxantrone, prednisone and siltuximab. Part 2 of the study is randomized portion (the study drug is assigned by chance), consisting of 2-arms. The experimental arm will consist of treatment with mitoxantrone, prednisone and siltuximab. The control arm will consist of treatment with mitoxantrone and prednisone. Mitoxantrone will be administered at a dose of 12 milligram per square meter (mg/m\^2) intravenously (into a vein) as a 30-minute infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1 of each 3-week cycle, until disease progression or unacceptable toxicity (any harmful effect of a drug) or up to 10 cycles (a maximum total dose of approximately 120 mg/m\^2). Siltuximab will be administered at a dose of 6 mg/kilogram intravenously as a 2-hour infusion, starting Day 1 of Cycle 1 to continue every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year. All participants will receive prednisone 5 mg twice daily starting with the first administration of Mitoxantrone. The duration of treatment will be a maximum of 12 months for cumulative dose. Radiologic assessments will be performed on Week 12 after the first study agent dosing, then every 9 weeks until the end of treatment and then once every 3 months until documented disease progression. Tumor (a mass in a specific area) response will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. There will be short-term follow-up visits (conducted monthly for 2 months), followed by long-term follow-up visits (conducted once every 3 months). Participants' safety will also be monitored throughout the study.
Following a standard of care allogeneic stem cell transplantation, participants will be started on Ruxolitinib. Ruxolitinib is administered orally 2 times per day at a fixed dose. Each study treatment cycle lasts 28 days. Up to 24 cycles.
Dose-expansion stage to confirm tolerability of ASTX660 at the RP2D using the every-other-week daily dosing regimen. Up to a total of 12 subjects (including the 3 or 6 subjects treated at the RP2D in Part 1) will be treated at the RP2D.
Participants will receive sotatercept via SC injection every 3 weeks at an initial dose of up to 45 mg and then at a maintenance dose of up to 90 mg using a weight-banded method during a 24-week treatment period. Participants will continue to take their background PAH therapy during the study.
Patients with late-stage NSCLC are often symptomatic, with specific pulmonary problems (eg, cough, breathlessness, hemoptysis) and general symptoms (eg. fatigue, weight loss) that can cause extreme distress to the patient. Therefore, improvements in disease-related symptoms and quality of life (QoL) are the key desired outcomes of medical management.7 Effective, palliative, low-toxicity with reasonable treatment cost for patients with advanced NSCLC are needed. Recently, more and more countries consider evidence of economic value along with clinical efficacy.

The epidermal growth factor receptor (EGFR) is a promising target for anticancer therapy because it is expressed or highly expressed in a variety of tumors, including NSCLC. 8,9 Furthermore, high levels of EGFR expression have been associated with a poor prognosis in lung cancer patients in several studies. 10-12 EGFR-targeted cancer therapies are currently being developed; strategies include inhibition of the intracellular tyrosine kinase domain of the receptor by small molecules such as gefitinib (Iressa \[ZD1839\]; AstraZeneca, Wilmington, DE).13 Iressa is an orally active, selective EGFR tyrosine kinase inhibitor that blocks signal transduction pathways implicated in the proliferation and survival of cancer cells.
The invention provides a medicinal wine for various rheumatic diseases and various pain, belonging to topical tinctures. The medicinal wine is used for injuries from falls, periarthris humeroscapularis, rheumatism, rheumatoid arthritis, waist leg pain, muscular dystrophy, wind-cold type headache, sciatica, herniation of lumbar intervertebral disc,   hyperosteogeny of cerv ical vertebrae, gastralgia of cold type, mastitis, dermatophytosis, postpartum rheumatism, and so on, with special effects of quick fever, strong percolation force, direct focus point, no allergy, reducing swelling and easing pain, eliminating damp and expelling wind and without any toxicity and side-effect. The features of the medicinal wine are  good behavior, quick effect and reliable curative effect. The medicinal wine is of combined use of A and B type. The mechanism is that in the guidance of alcohol, ova of cicada and digoucai lead all the medicine continually penetrating the hole of coat sweat gland using itself fevering function and entering subcutaneous tissue of corium to gradually take the rheumatism, sputum and the like out by meridian, blood and lymph fliud. After continual fevering for 3-6 hours, the side effects on wetting white and soaking of body surface are overcome to protect from skin damage.
Delayed Exercise Group will have exercise as intervention. People be tested before the start of, and after the end of the eight (8) weeks then after exercise intervention.
Buprenorphine and naloxone sublingual film are available in child resistant polyester/foil laminated pouches in four strengths: 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg or 12 mg/3 mg.

  * The 2 mg/0.5 mg buprenorphine and naloxone sublingual film is an orange rectangular film printed in white with “B2/N” containing 2.16 mg of buprenorphine HCl, USP equivalent to 2 mg of buprenorphine free base and 0.61 mg of naloxone HCl, USP dihydrate equivalent to 0.5 mg of naloxone free base. Each film is contained in a square, flat pouch that is imprinted with lot number and expiration date.
  * The 4 mg/1 mg buprenorphine and naloxone sublingual film is an orange rectangular film printed in white with “B4/N” containing 4.31 mg of buprenorphine HCl, USP equivalent to 4 mg of buprenorphine free base and 1.22 mg of naloxone HCl, USP dihydrate equivalent to 1 mg of naloxone free base. Each film is contained in a square, flat pouch that is imprinted with lot number and expiration date.
  * The 8 mg/2 mg buprenorphine and naloxone sublingual film is an orange rectangular film printed in white with “B8/N” containing 8.62 mg of buprenorphine HCl, USP equivalent to 8 mg of buprenorphine free base and 2.44 mg of naloxone HCl, USP dihydrate equivalent to 2 mg of naloxone free base. Each film is contained in a square, flat pouch that is imprinted with lot number and expiration date.
  * The 12 mg/3 mg buprenorphine and naloxone sublingual film is an orange rectangular film printed in white with “B12/N” containing 12.9 mg of buprenorphine HCl, USP equivalent to 12 mg of buprenorphine free base and 3.66 mg of naloxone HCl, USP dihydrate equivalent to 3 mg of naloxone free base. Each film is contained in a square, flat pouch that is imprinted with lot number and expiration date.
Previous studies showed that tight blood glucose control with insulin during intensive care reduced morbidity and mortality of surgical and medical intensive care patients. Blood sugar control with intravenous insulin may improve prognosis of patients undergoing cardiac surgery. It is not clear what the best insulin regimen is or what is the best blood sugar target in these patients. So far, most of researches have focused on adult patients but little on infants. The current prospective, randomized, controlled study will assess the impact of intensive insulin therapy on the outcome of infants undergoing cardiac surgery. On admission, patients will be randomly assigned to either strict normalization of blood glucose ( 110-150 mg/dl) with intensive insulin therapy or the conventional approach, in which blood glucose levels are maintained between 150 and 180 mg/dl.
In a large teaching hospital in Asia, stroke patients were divided into experimental group and control group by random allocation. The experimental group was given a mobile device education program, and the control group was routine nursing care. Two groups of stroke were discussed. Whether there are significant differences in knowledge, depression assessment, and self-efficacy assessment.

Hopefully, the intervention of mobile device education program can provide patients with a health education method that is accessible and can be repeatedly watched for learning. Hopefully, this education program may replace traditional health education leaflet, as well as reduce the workload of clinical nurses. It is hoped that this education program can effectively improve the self-care knowledge of patients with stroke, enhance self-efficacy, reduce depression symptoms, increase satisfaction with educational instructions, and ultimately prevent patients with stroke from experiencing any relapse to coexist with their stroke and enjoy a good quality of life.
BACKGROUND: Maternal obesity increases risk of infant mortality. Because obesity is highly inheritable, grandmaternal obesity could also play a role. However, it is unknown whether grandmaternal obesity is related to grandoffspring infant mortality risk.
OBJECTIVES: We investigated the associations of grandmaternal early pregnancy body mass index [BMI (in kg/m2)] and grandoffspring infant mortality risk.
METHODS: Using Swedish nationwide registers, we estimated infant mortality hazard ratios (HRs) by levels of maternal grandmaternal early pregnancy BMI among 315,461 singleton live-born grandoffspring. We examined whether the association was mediated through maternal body size. In a subset of 164,095 grandsoffspring we evaluated the role of paternal grandmaternal BMI. To explore whether factors shared within families explained these associations, we studied the relations of maternal or paternal full sisters' BMI and infant mortality.
RESULTS: Maternal grandmaternal overweight or obesity (BMI ≥ 25.0) was associated with increased grandoffspring infant mortality risk. Compared with the population median BMI (21.7), estimated adjusted hazard ratios [HRs (95% confidence interval [CI])] of grandoffspring mortality for BMI 25.0 and 30.0 were, respectively, 1.60 (1.14, 2.23) and 1.61 (1.13, 2.27). Maternal high birth weight-for-gestational age and early pregnancy obesity (BMI ≥ 30.0) were also associated with increased infant mortality risk. The association between maternal grandmaternal overweight or obesity and grandoffspring infant mortality was mostly (62%) mediated through maternal overweight or obesity. Maternal sisters' BMI was unrelated to infant mortality. Paternal grandmaternal obesity was associated with increased infant mortality risk (HR [95% CI] for BMI 30.0 compared with 21.7: 1.65 [1.02, 2.67]); associations with paternal sisters' BMI were not statistically significant.
CONCLUSIONS: Maternal grandmaternal overweight or obesity is associated with increased risk of grandoffspring infant mortality; factors shared within families may not play a major role. The association is mediated through the maternal early pregnancy BMI. Whether the association with paternal grandmaternal BMI is explained by shared familial factors warrants future confirmation.
BACKGROUND: Classical risk scoring systems underestimate the risk of cardiovascular disease in chronic kidney disease (CKD). Coronary artery calcium score (CACS) has improved prediction of cardiovascular events in patients with CKD. The maximal carotid plaque thickness (cPTmax) measured in ultrasound scans of the carotid arteries has demonstrated similar predictive value as CACS in the general population. This is the first study to investigate whether cPTmax can predict cardiovascular events in CKD and to compare the predictive value of cPTmax and CACS in CKD.
METHOD: Two hundred patients with CKD stage 3 from the Copenhagen CKD Cohort underwent ultrasound scanning of the carotid arteries. The assessment consisted of locating plaque and measuring the thickest part of the plaque, cPTmax. Based on the distribution of cPTmax, the participants were divided into 3 groups: No plaques, cPTmax 1.0-1.9 mm and cPTmax > 1.9 mm (median cPTmax = 1.9 mm among patients with plaques). To measure CACS, 175 of the patients underwent a non-contrast CT scan of the coronary arteries. The follow-up time spanned between the ultrasound scan and a predefined end-date or the time of first event, defined as a composite of major cardiovascular events or death of any cause (MACE).
RESULTS: The median follow-up time was 5.4 years during which 45 patients (22.5%) developed MACE. In a Cox-regression adjusted for classical cardiovascular risk factors, patients with cPTmax > 1.9 mm had a significantly increased hazard ratio of MACE (HR 3.2, CI: 1.1-9.3), p = 0.031) compared to patients without plaques. C-statistics was used to evaluate models for predicting MACE. The improvement in C-statistics was similar for the two models including classical cardiovascular risk factors plus cPTmax (0.247, CI: 0.181-0.312) and CACS (0.243, CI: 0.172-0.315), respectively, when compared to a model only controlled for time since baseline (a Cox model with no covariates).
CONCLUSION: Our results indicate that cPTmax may be useful for predicting MACE in CKD. cPTmax and CACS showed similar ability to predict MACE.
For early-stage hormone receptor (HR)-positive and HER2-negative breast cancer, tools to estimate treatment benefit include free and publicly available algorithms (e.g., PREDICT 2.1) and expensive molecular assays (e.g., Oncotype DX). There remains a need to identify patients who de-rive the most benefit from molecular assays and where this test may be of poor value. In this multicenter prospective cohort study, we evaluated whether use of PREDICT 2.1 would impact physician decision making. For the first 6 months of the study, data on physician use of both PREDICT 2.1 and Oncotype DX ordering were collected on all newly diagnosed patients eligible for molecular testing. After 6 months, an educational intervention was undertaken to see if providing physicians with PREDICT 2.1 results affects the frequency of Oncotype DX requests. A total of 602 patients across six cancer centers in Ontario, Canada were recruited between March 2020 and November 2021. Providing PREDICT 2.1 results and an educational intervention did not alter the ordering of an Oncotype DX. For patients with low clinical risk, either by clinico-pathologic features or by PREDICT 2.1, the probability of obtaining a high Oncotype DX recurrence score was substantially lower compared to patients with high-clinical-risk disease. The introduction of an educational intervention had no impact on molecular assay requests. However, routine ordering of molecular assays for patients with low-clinical-risk disease is of poor value.
PURPOSE: To obtain the subject extract having low proanthocyanin content causing toxic problem by removing biflavonoids and a hydrophobic substance from an extract of Ginkgo biloba leaves and carrying out alkalinization and subsequent removal treatment of an insoluble fraction. CONSTITUTION: Ginkgo biloba leaves are ground and subjected to an extraction treatment with an aqueous ketone solvent and the resultant extracted solution is concentrated to precipitate biflavonoids and a hydrophobic substance, which are then removed by filtration. The filtrate is alkalinized (preferably until pH value reaches about 14) to precipitate proanthocyanin and the insoluble fraction is removed by filtration. Then, the filtrate is acidified and subjected to liquid- liquid extraction by using a 4-6C ketone (e.g. methyl ethyl ketone) in the presence of ammonium sulfate and a ketone phase is dried to provide the objective extract of Ginkgo biloba leaves. The extract is useful for treatment of disorder of pulse, capillary circulation and venous circulation, especially disorder of peripheral and cerebral circulation of aged person.
The invention discloses nipple protection cream special for dairy cows. The nipple protection cream consists of the following substances in percentage by mass: 4-15 percent of Chinese angelica, 4-15 percent of marsh marigold, 2-10 percent of liquoric root, 2-10 percent of borax, 3-10 percent of glycerol, 3-10 percent of wool fat and the balance of Vaseline. A preparation method of the nipple protection cream is further disclosed. The preparation method comprises the following steps: grinding borax, and sieving through a 100-mesh sieve for later use; smashing Chinese angelica, marsh marigold and liquoric root, soaking, performing ultrasonic extraction, filtering residues out, combining filtrate, concentrating into thick paste in vacuum under reduced pressure, adding glycerol, and mixing uniformly; heating the wool fat and Vaseline for melting, adding a medicinal concentrated solution and ground borax respectively under stirring after the temperature drops to 60 DEG C, and continually stirring till paste is formed by means of condensation. The nipple protection cream is mainly used for protecting nipple skin of dairy cows, and has excellent effects of moistening, preserving moisture, disinfecting, diminishing swelling, relieving pain and resisting inflammation on the breast and nipple skin of dairy cows. By using the nipple protection cream, crack, freezing injury and infection of the nipples of dairy cows can be effectively prevented particularly in winter, a barrier is provided for nipples, and mastitis of dairy cows is prevented.
The study will comprise of 2 parts. A dose escalation and a dose expansion part. All patients in the dose escalation part will have a pharmacokinetic (PK) run-in period of 7 days receiving imatinib monotherapy. Patients will receive increasing doses of BYL719 (200, 300, 400 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. Approximately 35 patients will enter the expansion phase.
The present invention relates to a living cordycepin product and a method for artificially culturing cordycepin sporophores. High-efficiency prolific strains are obtained by collecting, separating, screening and purifying superior strains (polypides), sporophores are cultured by adding culture medium under the condition temperature control, and cordyceps are produced. In addition, the raised living bodies of silkworm chrysalises are vaccinated, and the cultured rejuvenescent cordyceps are checked, packaged, warehoused and output to sell after led out for reproduction. The present invention is characterized in that strains are injected into culture medium filled in PP bottles, sporophores are cultured under the conditions of illumination and temperature control, and then, living cordyceps products are produced. The stromata of living cordyceps acquired with the method of the present invention are salmon and cylindrical, and are 4.5 to 8.5cm in length and 3 to 4mm in diameter, and the head part is cylindrical, clavate and columnar. The nutrient and medicinal value achieved by the living cordyceps artificially cultured in the present invention is higher than that of natural cordyceps, the content of cordycepin and SOD (superoxide dismutase) is higher, the content of aweto polysaccharide is 4.5 times higher than that of natural cordyceps, and the content of SOD is 3000 u/g, which is about 80 times higher than that of natural cordyceps. Therefore, the present invention is a tonic product that has the advantages of low cost, high efficacy, cheap price, and high additive value.
Care as Usual: In the CAU control group, participants are free to continue to engage with any treatment they require. However, they will be offered access to somnovia after 6 months post-baseline.
[Problem] The present invention addresses the problem of providing: a dispersing agent which is environmentally friendly and which exhibits good dispersing properties as a result of using a carboxymethylated xylan which is obtained by methylating a xylan, said dispersing properties for dispersing a poorly soluble or insoluble substance; and a dispersion liquid. [Solution] The present invention is characterized by using a carboxymethylated xylan obtained by subjecting a xylan to a carboxymethylation treatment. In this case, the xylan may be a glucuronoxylan. In addition, the CM conversion degree of the carboxymethylated xylan is preferably 0.1-0.4. In a case where a carboxymethylated xylan obtained by subjecting a glucuronoxylan to a carboxymethylation treatment is used and the CM conversion degree of the carboxymethylated xylan is 0.1-0.4, it is possible to obtain a dispersing agent having excellent dispersing properties. The poorly soluble or insoluble substance may be carbon nanotubes, graphenes, β-carotene or phthalocyanine.